8-K Announcements
6Material company update
May 1, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Mar 17, 2026·SEC
Curis, Inc.(CRIS)Earnings, Financials & Key Ratios
CRIS•NASDAQ
$0.57
$75M mkt cap·Price updated May 6, 2026
AboutCuris, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Show more
- Revenue$9M-13.4%
- EBITDA-$33M+26.2%
- Net Income-$8M+82.5%
- EPS (Diluted)-0.58+91.6%
- Gross Margin99.52%+0.4%
- EBITDA Margin-346.64%+14.7%
- Operating Margin-348.43%+14.7%
- Net Margin-80.29%+79.8%
- ROE-138.81%+78.1%
- Debt/Equity0.30
- Interest Coverage-15.06+78.3%
CRIS Key Insights
Curis, Inc. (CRIS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 24.0%
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 13.7x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CRIS Price & Volume
Curis, Inc. (CRIS) stock price & volume — 10-year historical chart
Loading chart...
CRIS Growth Metrics
Curis, Inc. (CRIS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years1.83%
5 Years-2.71%
3 Years-2.42%
TTM-13.43%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM82.53%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM83.07%
Return on Capital
10 Years-82.35%
5 Years-95.79%
3 Years-137.21%
Last Year-233.94%
CRIS Peer Comparison
Curis, Inc. (CRIS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TGTX | 5.7B | 36.10 | 240.67 | 40.8% | 13.31% | 21.87% | 1.14 | |
 KPTI | 81.89M | 9.41 | -0.52 | 0.57% | -87.43% | |||
 MGNX | 199.45M | 3.15 | -2.67 | 0.78% | -49.91% | -120.2% | 0.66 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 PRTA | 602.39M | 11.19 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 PTCT | 5.39B | 65.04 | 8.36 | 114.51% | 39.44% | 13.02% | ||
 FATE | 272.25M | 2.36 | -2.05 | -51.24% | -20.51% | -65.79% | 0.38 | |
 AGEN | 147.29M | 4.17 | -1226.47 | 10.37% | 0.1% |
Compare CRIS vs Peers
Curis, Inc. (CRIS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRIS Income Statement
Curis, Inc. (CRIS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 9.9M | 10.43M | 10M | 10.84M | 10.65M | 10.16M | 10.02M | 10.91M | 9.44M |
| Revenue Growth % | 31.5% | 5.35% | -4.07% | 8.31% | -1.72% | -4.57% | -1.37% | 8.83% | -13.43% |
| Cost of Goods Sold | 496K | 563K | 503K | 534K | 533K | 257K | 212K | 98K | 45K |
| COGS % of Revenue | 5.01% | 5.4% | 5.03% | 4.93% | 5.01% | 2.53% | 2.12% | 0.9% | 0.48% |
| Gross Profit | 9.4M▲ 0% | 9.87M▲ 4.9% | 9.5M▼ 3.7% | 10.3M▲ 8.4% | 10.12M▼ 1.8% | 9.9M▼ 2.1% | 9.81M▼ 0.9% | 10.81M▲ 10.2% | 9.4M▼ 13.1% |
| Gross Margin % | 94.99% | 94.6% | 94.97% | 95.07% | 94.99% | 97.47% | 97.88% | 99.1% | 99.52% |
| Gross Profit Growth % | 31.9% | 4.92% | -3.69% | 8.42% | -1.8% | -2.09% | -0.95% | 10.18% | -13.06% |
| Operating Expenses | 59.16M | 39.2M | 33.86M | 35.2M | 52.18M | 62.92M | 58.14M | 55.35M | 42.34M |
| OpEx % of Revenue | 597.72% | 375.89% | 338.43% | 324.86% | 490.01% | 619.22% | 580.1% | 507.44% | 448.43% |
| Selling, General & Admin | 25.82M | 14.79M | 11.55M | 12.13M | 17.3M | 19.65M | 18.65M | 16.79M | 14.05M |
| SG&A % of Revenue | 260.84% | 141.78% | 115.5% | 111.96% | 162.43% | 193.35% | 186.04% | 153.92% | 148.75% |
| Research & Development | 33.34M | 24.41M | 22.3M | 23.07M | 34.88M | 43.28M | 39.5M | 38.56M | 28.25M |
| R&D % of Revenue | 336.88% | 234.11% | 222.93% | 212.9% | 327.58% | 425.87% | 394.05% | 353.52% | 299.21% |
| Other Operating Expenses | -104K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 45K |
| Operating Income | -49.76M▲ 0% | -29.33M▲ 41.1% | -24.36M▲ 17.0% | -24.9M▼ 2.2% | -42.06M▼ 68.9% | -53.02M▼ 26.0% | -48.33M▲ 8.8% | -44.54M▲ 7.8% | -32.9M▲ 26.1% |
| Operating Margin % | -502.73% | -281.29% | -243.46% | -229.79% | -395.01% | -521.75% | -482.21% | -408.34% | -348.43% |
| Operating Income Growth % | 14.26% | 41.05% | 16.97% | -2.23% | -68.95% | -26.04% | 8.84% | 7.84% | 26.13% |
| EBITDA | -49.52M | -29.16M | -24.23M | -24.75M | -41.91M | -52.79M | -48.08M | -44.34M | -32.73M |
| EBITDA Margin % | -500.35% | -279.59% | -242.21% | -228.46% | -393.53% | -519.45% | -479.67% | -406.48% | -346.64% |
| EBITDA Growth % | 14.38% | 41.13% | 16.89% | -2.16% | -69.29% | -25.96% | 8.92% | 7.78% | 26.18% |
| D&A (Non-Cash Add-back) | 235K | 177K | 125K | 144K | 158K | 233K | 255K | 203K | 169K |
| EBIT | -49.35M | -28.65M | -27.3M | -24.81M | -40.96M | -51.9M | -45.39M | -42.77M | -32.9M |
| Net Interest Income | -3.45M | -3.24M | -4.23M | -5.03M | -4.26M | -3.65M | 919K | 1.15M | -1.87M |
| Interest Income | 513K | 684K | 614K | 63K | 211K | 1.12M | 2.94M | 1.77M | 316K |
| Interest Expense | 3.97M | 3.93M | 4.85M | 5.09M | 4.47M | 4.77M | 2.02M | 615K | 2.19M |
| Other Income/Expense | -3.56M | -3.24M | -7.79M | -5.01M | -3.37M | -3.65M | 919K | 1.15M | 25.32M |
| Pretax Income | -53.32M▲ 0% | -32.58M▲ 38.9% | -32.14M▲ 1.3% | -29.91M▲ 6.9% | -45.44M▼ 51.9% | -56.67M▼ 24.7% | -47.41M▲ 16.3% | -43.39M▲ 8.5% | -7.58M▲ 82.5% |
| Pretax Margin % | -538.66% | -312.38% | -321.28% | -276.03% | -426.67% | -557.69% | -473.04% | -397.77% | -80.29% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -53.32M▲ 0% | -32.58M▲ 38.9% | -32.14M▲ 1.3% | -29.91M▲ 6.9% | -45.44M▼ 51.9% | -56.67M▼ 24.7% | -47.41M▲ 16.3% | -43.39M▲ 8.5% | -7.58M▲ 82.5% |
| Net Margin % | -538.66% | -312.38% | -321.28% | -276.03% | -426.67% | -557.69% | -473.04% | -397.77% | -80.29% |
| Net Income Growth % | 11.74% | 38.9% | 1.33% | 6.95% | -51.92% | -24.73% | 16.34% | 8.49% | 82.53% |
| Net Income (Continuing) | -53.32M | -32.58M | -32.14M | -29.91M | -45.44M | -56.67M | -47.41M | -43.39M | -7.58M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -35.75▲ 0% | -19.67▲ 45.0% | -19.37▲ 1.5% | -12.29▲ 36.6% | -9.92▲ 19.3% | -12.14▼ 22.4% | -8.96▲ 26.2% | -6.88▲ 23.2% | -0.58▲ 91.6% |
| EPS Growth % | 21.43% | 44.98% | 1.53% | 36.55% | 19.28% | -22.38% | 26.19% | 23.21% | 91.57% |
| EPS (Basic) | -35.75 | -19.67 | -19.37 | -12.29 | -9.92 | -12.14 | -8.96 | -6.88 | -0.58 |
| Diluted Shares Outstanding | 1.49M | 1.66M | 1.66M | 2.43M | 4.58M | 4.67M | 5.29M | 6.31M | 131.64M |
| Basic Shares Outstanding | 1.49M | 1.66M | 1.66M | 2.43M | 4.58M | 4.67M | 5.29M | 6.31M | 131.64M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CRIS Balance Sheet
Curis, Inc. (CRIS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 64.29M | 27.13M | 25M | 172.75M | 122.38M | 92.12M | 60.91M | 26.39M | 5.06M |
| Cash & Short-Term Investments | 60.23M | 24.27M | 20.54M | 168.49M | 115.88M | 85.62M | 56.33M | 20M | 5.06M |
| Cash Only | 38.29M | 23.64M | 15.43M | 129.61M | 40.01M | 19.66M | 26.68M | 20M | 5.06M |
| Short-Term Investments | 21.94M | 634K | 5.11M | 38.88M | 75.87M | 65.97M | 29.65M | 0 | 0 |
| Accounts Receivable | 3.07M | 2.86M | 3.24M | 3.04M | 3.22M | 2.98M | 2.79M | 3.35M | 0 |
| Days Sales Outstanding | 113.32 | 100.25 | 118.36 | 102.51 | 110.5 | 106.86 | 101.75 | 112.06 | - |
| Inventory | 0 | -827K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 153K | 0 | 0 | 3.52M | 1.78M | 3.04M | 0 |
| Total Non-Current Assets | 9.5M | 10.23M | 10.1M | 31.61M | 39.93M | 16.73M | 16.37M | 14.88M | 12.55M |
| Property, Plant & Equipment | 366K | 267K | 303K | 7.24M | 6.25M | 5.09M | 3.49M | 3.39M | 3.57M |
| Fixed Asset Turnover | 27.04x | 39.06x | 33.02x | 1.50x | 1.70x | 2.00x | 2.87x | 3.21x | 2.65x |
| Goodwill | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 153K | 153K | 0 | 14.56M | 23.96M | 0 | 0 | 544K | 544K |
| Other Non-Current Assets | 156K | 982K | 819K | 819K | 726K | 2.66M | 3.9M | 1.96M | -544K |
| Total Assets | 73.8M▲ 0% | 37.37M▼ 49.4% | 35.11M▼ 6.0% | 204.36M▲ 482.1% | 162.3M▼ 20.6% | 108.85M▼ 32.9% | 77.28M▼ 29.0% | 41.27M▼ 46.6% | 19.97M▼ 51.6% |
| Asset Turnover | 0.13x | 0.28x | 0.28x | 0.05x | 0.07x | 0.09x | 0.13x | 0.26x | 0.47x |
| Asset Growth % | 27.78% | -49.37% | -6.04% | 482.1% | -20.58% | -32.93% | -29% | -46.6% | -51.62% |
| Total Current Liabilities | 14.1M | 6.38M | 6.54M | 10.08M | 13.44M | 10.01M | 22.02M | 19.03M | 14.08M |
| Accounts Payable | 5.42M | 2.91M | 4.46M | 4.17M | 6.42M | 3.19M | 3.17M | 3.02M | 12.89M |
| Days Payables Outstanding | 3.99K | 1.89K | 3.24K | 2.85K | 4.39K | 4.53K | 5.46K | 11.26K | 104.52K |
| Short-Term Debt | 5.89M | 6.88M | 0 | 557K | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | -6.87M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 606K | 683K | 1.41M | 2.64M | 3.26M | 0 | 8.5M | 7.56M | -1.62M |
| Current Ratio | 4.56x | 4.25x | 3.82x | 17.14x | 9.11x | 9.20x | 2.77x | 1.39x | 0.36x |
| Quick Ratio | 4.56x | 4.38x | 3.82x | 17.14x | 9.11x | 9.20x | 2.77x | 1.39x | 0.36x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 35.7M | 35.48M | 62.48M | 63.61M | 58.16M | 52.28M | 35.59M | 28.24M | 939K |
| Long-Term Debt | 35.67M | 28.6M | 0 | 334K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 5.04M | 4.36M | 2.8M | 1.49M | 1.62M | 428K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 511K |
| Other Non-Current Liabilities | 34K | 11K | 62.48M | 58.23M | 53.8M | 49.48M | 34.1M | 26.62M | 0 |
| Total Liabilities | 49.8M | 41.86M | 69.02M | 73.69M | 71.59M | 62.3M | 57.61M | 47.26M | 14.5M |
| Total Debt | 41.55M | 35.48M | 166K | 7.66M | 5.04M | 3.94M | 2.79M | 2.95M | 1.62M |
| Net Debt | 3.27M | 11.85M | -15.26M | -121.95M | -34.97M | -15.72M | -23.89M | -17.04M | -3.44M |
| Debt / Equity | 1.73x | - | - | 0.06x | 0.06x | 0.08x | 0.14x | - | 0.30x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -12.44x | -7.30x | -5.63x | -4.87x | -9.16x | -10.88x | -22.48x | -69.55x | -15.06x |
| Total Equity | 23.99M▲ 0% | -4.5M▼ 118.7% | -33.91M▼ 654.2% | 130.67M▲ 485.3% | 90.71M▼ 30.6% | 46.55M▼ 48.7% | 19.67M▼ 57.7% | -6M▼ 130.5% | 5.46M▲ 191.1% |
| Equity Growth % | -18.02% | -118.74% | -654.25% | 485.33% | -30.58% | -48.68% | -57.75% | -130.49% | 191.06% |
| Book Value per Share | 16.09 | -2.72 | -20.44 | 53.70 | 19.81 | 9.97 | 3.72 | -0.95 | 0.04 |
| Total Shareholders' Equity | 23.99M | -4.5M | -33.91M | 130.67M | 90.71M | 46.55M | 19.67M | -6M | 5.46M |
| Common Stock | 1.65M | 332K | 332K | 915K | 916K | 48K | 59K | 85K | 129K |
| Retained Earnings | -952.26M | -984.84M | -1.02B | -1.05B | -1.09B | -1.15B | -1.2B | -1.24B | -1.25B |
| Treasury Stock | -1.52M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2K | 0 | 0 | -3K | -109K | -186K | 229K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRIS Cash Flow Statement
Curis, Inc. (CRIS) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -48.35M | -30.07M | -26.2M | -25.74M | -37.62M | -54.34M | -38.43M | -39.56M | -27.2M |
| Operating CF Margin % | -488.53% | -288.31% | -261.95% | -237.55% | -353.26% | -534.71% | -383.46% | -362.7% | -288.05% |
| Operating CF Growth % | -35.03% | 37.82% | 12.84% | 1.78% | -46.16% | -44.44% | 29.27% | -2.94% | 31.25% |
| Net Income | -53.32M | -32.58M | -32.14M | -29.91M | -45.44M | -56.67M | -47.41M | -43.39M | -7.58M |
| Depreciation & Amortization | 235K | 177K | 125K | 144K | 158K | 1.39M | 255K | 187K | 169K |
| Stock-Based Compensation | 5.36M | 3.94M | 2.66M | 2.7M | 5.28M | 0 | 6M | 5.93M | 4.02M |
| Deferred Taxes | 0 | 7K | 0 | 24K | 1.4M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 91K | -112K | 4.71M | 255K | -26K | 7.76M | -55K | 1.43M | -25.56M |
| Working Capital Changes | -723K | -1.5M | -1.56M | 1.05M | 1M | -6.82M | 2.78M | -3.72M | 1.75M |
| Change in Receivables | -614K | 209K | -380K | 201K | -181K | 249K | 181K | -555K | -1.03M |
| Change in Inventory | -49.92M | 1.87M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -376K | -1.87M | 60K | 1M | 4.96M | -3.88M | 3.34M | -2.08M | 2.55M |
| Cash from Investing | -3.63M | 21.37M | -4.46M | -49.05M | -47.9M | 33.02M | 37.79M | 29.44M | 2.5M |
| Capital Expenditures | -188K | -85K | -41K | -677K | 0 | -416K | 0 | 0 | 0 |
| CapEx % of Revenue | 1.9% | 0.82% | 0.41% | 6.25% | - | 4.09% | - | - | - |
| Acquisitions | 188K | 85K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -188K | -85K | 0 | 0 | 0 | 0 | 0 | 0 | 2.5M |
| Cash from Financing | 64.23M | -5.96M | 23.27M | 188.81M | -4.17M | 867K | 7.58M | 3.44M | 9.77M |
| Debt Issued (Net) | 21.74M | -6.1M | 23.2M | 891K | 0 | -4.97M | 0 | -8.59M | -5.59M |
| Equity Issued (Net) | 41.55M | 0 | 68K | 193.22M | 300K | 5.84M | 14.12M | 12.02M | 15.35M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 946K | 143K | 0 | -5.3M | -4.47M | 0 | -6.54M | 0 | 0 |
| Net Change in Cash | 12.25M▲ 0% | -14.65M▼ 219.6% | -8.05M▲ 45.0% | 114.03M▲ 1516.0% | -89.69M▼ 178.7% | -20.36M▲ 77.3% | 6.93M▲ 134.1% | -6.68M▼ 196.4% | -14.94M▼ 123.5% |
| Free Cash Flow | -48.54M▲ 0% | -30.15M▲ 37.9% | -26.25M▲ 12.9% | -26.42M▼ 0.6% | -37.62M▼ 42.4% | -54.75M▼ 45.5% | -38.43M▲ 29.8% | -39.56M▼ 2.9% | -27.2M▲ 31.2% |
| FCF Margin % | -490.43% | -289.13% | -262.36% | -243.8% | -353.26% | -538.8% | -383.46% | -362.7% | -288.05% |
| FCF Growth % | -34.32% | 37.89% | 12.95% | -0.65% | -42.41% | -45.55% | 29.8% | -2.94% | 31.25% |
| FCF per Share | -32.55 | -18.21 | -15.82 | -10.86 | -8.22 | -11.73 | -7.26 | -6.27 | -0.21 |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.92x | 0.82x | 0.86x | 0.83x | 0.96x | 0.81x | 0.91x | 3.59x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRIS Key Ratios
Curis, Inc. (CRIS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -128.84% | -200.22% | -334.15% | - | -61.82% | -41.05% | -82.58% | -143.19% | -634.71% | -138.81% |
| Return on Invested Capital (ROIC) | -110.66% | -148.25% | -127.12% | - | - | -97.89% | -91.87% | -272.36% | - | - |
| Gross Margin | 94.7% | 94.99% | 94.6% | 94.97% | 95.07% | 94.99% | 97.47% | 97.88% | 99.1% | 99.52% |
| Net Margin | -802.59% | -538.66% | -312.38% | -321.28% | -276.03% | -426.67% | -557.69% | -473.04% | -397.77% | -80.29% |
| Debt / Equity | 0.68x | 1.73x | - | - | 0.06x | 0.06x | 0.08x | 0.14x | - | 0.30x |
| Interest Coverage | -20.75x | -12.44x | -7.30x | -5.63x | -4.87x | -9.16x | -10.88x | -22.48x | -69.55x | -15.06x |
| FCF Conversion | 0.59x | 0.91x | 0.92x | 0.82x | 0.86x | 0.83x | 0.96x | 0.81x | 0.91x | 3.59x |
| Revenue Growth | -4.46% | 31.5% | 5.35% | -4.07% | 8.31% | -1.72% | -4.57% | -1.37% | 8.83% | -13.43% |
CRIS SEC Filings & Documents
Curis, Inc. (CRIS) SEC filings — annual & quarterly reports (10-K, 10-Q)
CRIS Frequently Asked Questions
Curis, Inc. (CRIS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Curis, Inc. (CRIS) reported $9.4M in revenue for fiscal year 2025. This represents a 194% increase from $3.2M in 1999.
Curis, Inc. (CRIS) saw revenue decline by 13.4% over the past year.
Curis, Inc. (CRIS) reported a net loss of $7.6M for fiscal year 2025.
Dividend & Returns
Curis, Inc. (CRIS) has a return on equity (ROE) of -138.8%. Negative ROE indicates the company is unprofitable.
Curis, Inc. (CRIS) had negative free cash flow of $27.2M in fiscal year 2025, likely due to heavy capital investments.
Explore More CRIS
Curis, Inc. (CRIS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates